Please activate JavaScript!
Please install Adobe Flash Player, click here for download

ePaper - CCN Ausgabe - Number 2012-4

Ausgabe 4 - Number 4 · 2012 CCCCCCathlab &athlab &athlab &athlab &athlab &athlab & CCCCCCardiovascularardiovascularardiovascularardiovascularardiovascularardiovascularardiovascularardiovascularardiovascularardiovascularardiovascularardiovascular NNNNNNewsewsewsewsewsews CCNCCNCCNCCNCCNCCNCCNCCNCCNCCNCCNCCN PRODUCT NEWS • Privately held company • Corporate headquarters located in Laguna Hills, CA • Developed innovative catheter-based renal denervation system for the treatment of medication-resistant hypertension • V2 Renal Denervation System™ CE marked and we expect to initiate a full launch in CE Mark countries in 2013 • Over-the-wire balloon with mounted RF electrodes • Balloon sizes 4 – 7 mm • 30 seconds ablation time • All electrodes deliver energy simultaneously • RF electrodes automatically deactivated when not in contact with the artery wall • Bi-polar technology obviates the need for a grounding pad • Algorithm controls temperature at precisely 68°C • One button operation Boston Scientific AcquiresVessixVascular, Inc. for Renal Denervation Note: This presentation contains products currently in development and not for sale in the United States. These products are subject to future regulatory review prior to market release. Boston Scientific makes no claims about the safety, efficacy or availability of unapproved devices shown in this presentation. 54